Insilico's San Francisco team was thrilled to have a recent photo shoot with E24 - #Norway 's largest online newspaper for economics and business. Thank you Linn Kongsli Hillestad for featuring Insilico in your upcoming story on the latest advances in #AI drug discovery!

A new analysis from BiopharmaTrend compares the #novelty of #targets that #AI drug discovery companies are pursuing for their leading #drug programs, from low novelty to AI-discovered very novel targets like Insilico's TNIK for IPF. biopharmatrend.com/ai-drug-discov…

Congrats to Andrea Maier on a new study in Geroscience exploring the link between biological age & levels of inactivity in hospitalized older adults using SenoClock from DeepLongevity. Dr. Maier will be at the upcoming ARDD Meeting. link.springer.com/article/10.100… Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)

Insilico researchers used #genAI to discover a new class of Polθ inhibitors for #BRCA -deficient cancers. The molecules exhibited significant enzymatic and cellular potency and promising druglike properties, pointing to a novel strategy for targeting Polθ. eurekalert.org/news-releases/…

Announcing Generative AI for Sustainability. Insilico founder & CEO Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) will be making a number of stops in the #MENA region to discuss how #biotech and generative #AI are driving solutions to #climatechange , including at the World Future Energy Summit. #WFES2024 eurekalert.org/news-releases/…

Meet Insilico's Global Head of AI Platforms Petrina Kamya, Ph.D. at the Bio-IT World Expo! Petrina presents as part of a panel Wed., April 17, 11:40am on 'End-to-End Acceleration for AI & Drug Discovery' sponsored by Oracle. bio-itworldexpo.com #BioITExpo

A research team from University of Toronto, Insilico & Zapata AI have for the first time used a  #quantum computer to discover drug candidates for #KRAS -mutant #cancer genes. They used a hybrid quantum-classical #AI algorithm to generate a new and novel molecule. acceleration.utoronto.ca/news/universit…

🌐🩺 CEO Alex Zhavoronkov (Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)) of Insilico Medicine, a biotech firm pioneering AI-driven drug discovery, is speaking at the Future Health Summit during Abu Dhabi Global Healthcare Week. Insilico, having raised $400M, is advancing 11 preclinical candidates and commenced

Advancing the next generation of cancer immunotherapy with AI.

Insilico has designed a novel PTPN2/N1 #cancer #immunotherapy inhibitor with its generative #AI chemistry engine Chemistry42 using a fast-follow strategy. The findings were published in EJMC. medicalxpress.com/news/2024-04-t…

How Alan Aspuru-Guzik of Acceleration Consortium (AC) worked w/ Insilico's #genAI platform to discover & design a new inhibitor for liver cancer in under 30 days. Insilico is advancing many of these discoveries into trials, including potential #cancer treatments. CTV youtube.com/watch?v=04YsG_…

👏 Thank you #drugdiscoverychemistry for bringing together medicinal & biophysical chemists to discuss discovery & optimization of small molecule drugs. Petrina Kamya, PhD, Head of AI Platforms at Insilico, discussed AI for #cancer & co-led a course on #genAI for drug discovery.

New algorithm alert. Insilico researchers published on Quantum-assisted Fragment-based Automated Structure Generator - using advanced chemoinformatic techniques to construct novel small-molecule #cancer inhibitors from molecular fragments. Frontiers eurekalert.org/news-releases/…

At #AACR ? Connect w/ Insilico & see our 5 AI-designed anti- #cancer assets avail for partnering & out-licensing:
▪ novel pan-TEAD inhibitor
▪ novel WRN inhibitor
▪ novel HPK1 inhibitor
▪ novel dual FGFR2/3 inhibitor
▪ novel KIF18A inhibitor
Email [email protected] #AACR 2024

Thank you Nature Aging! Excellent examination of the role of #aging research as a platform for #AI target discovery and the development of the first fully generative AI drug to make it to Phase II trials.

ISM9682A - a novel, potent, selective, #AI -designed KIF18A inhibitor - is positioned as a promising therapeutic for cancers with chromosome instability. It's one of 5 molecules Insilico will show AACR in San Diego April 5-10. Interested? [email protected] #AACR24 #cancer

A Superbio.ai Scientist Spotlight of Petrina Kamya, Ph.D.! The Superbio team interviewed Insilico's Global Head of AI Platforms about her journey -- from her training in quantum #chemistry to the many ways #AI is changing the game for drug discovery. blog.superbio.ai/superbio-scien…

A new story in Genetic Engineering & Biotechnology News looks at how Insilico is using #AI to design novel #cancer inhibitors for treatment-resistant cancers. 5 of these programs available for partnering and out-licensing will be presented at #AACR2024 April 5-10. Contact [email protected] genengnews.com/topics/cancer/…

ISM9182A - a novel, potent, selective, #AI -designed HPK1 inhibitor positioned as a promising immuno-oncology therapeutic. It's one of 5 molecules Insilico will show at AACR in San Diego April 5-10. Interested? [email protected] #AACR24

New BiopharmaTrend report offers an in-depth look at #AI drug discovery #pipelines . 'The majority of Insilico’s AI-discovered programs are first-in-class #drug candidates for high-novelty targets or best-in-class candidates for moderately novel targets.' biopharmatrend.com/ai-drug-discov…

A new story in Salon on the NOVA | PBS doc 'A.I. Revolution' looks at recent advances in AI technology and how fear - driven by lack of understanding and nuanced coverage - is drowning out many positive advances, particularly in medicine & climate science.
salon.com/2024/03/29/nov…